Evidence map›Paper›PMID 35123061›Full record

ReviewNitric oxide : biology and chemistry2022

Nitric oxide: Clinical applications in critically ill patients.

Simone Redaelli, Aurora Magliocca, Rajeev Malhotra, Giuseppe Ristagno, Giuseppe Citerio, Giacomo Bellani, Lorenzo Berra, Emanuele Rezoagli

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nitric oxide : biology and chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. NO Addition during Gas Oxygenation Reduces Liver and Kidney Injury during Prolonged Cardiopulmonary Bypass.Pathophysiology : the official journal of the International Society for Pathophysiology · 2023
    Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Simone RedaelliSchool of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
Aurora MaglioccaDepartment of Medical Physiopathology and Transplants, University of Milan, Milano, Italy.
Rajeev MalhotraDivision of Cardiology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Giuseppe RistagnoDepartment of Medical Physiopathology and Transplants, University of Milan, Milano, Italy; Department of Anesthesiology, Intensive Care and Emergency, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Giuseppe CiterioSchool of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy; Neuroscience Department, NeuroIntensive Care Unit, San Gerardo Hospital, ASST Monza, Monza, Italy.
Giacomo BellaniSchool of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy; Department of Emergency and Intensive Care, ECMO Center, San Gerardo University Hospital, Monza, Italy.
Lorenzo BerraHarvard Medical School, Boston, MA, USA; Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, MA, USA; Respiratory Care Department, Massachusetts General Hospital, Boston, MA, USA.
Emanuele RezoagliSchool of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy; Department of Emergency and Intensive Care, ECMO Center, San Gerardo University Hospital, Monza, Italy. Electronic address: emanuele.rezoagli@unimib.it.
Azienda Ospedaliera San Gerardo · ITHarvard University · USUniversity of Milan · ITUniversity of Milano-Bicocca · IT

Funding

The Role of Histone Deacetylase 9 in Vascular CalcificationR01HL142809 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI MALHOTRA, RAJEEV · 2018 to 2022
$4.0M
Hemolysis and Nitric OxideK23HL128882 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI BERRA, LORENZO · 2017 to 2021
$1.0M
NHLBI NIH HHS K23 HL128882NHLBI NIH HHS R01 HL142809
6 · The paper itself

Abstract

Inhaled nitric oxide (iNO) acts as a selective pulmonary vasodilator and it is currently approved by the FDA for the treatment of persistent pulmonary hypertension of the newborn. iNO has been demonstrated to effectively decrease pulmonary artery pressure and improve oxygenation, while decreasing extracorporeal life support use in hypoxic newborns affected by persistent pulmonary hypertension. Also, iNO seems a safe treatment with limited side effects. Despite the promising beneficial effects of NO in the preclinical literature, there is still a lack of high quality evidence for the use of iNO in clinical settings. A variety of clinical applications have been suggested in and out of the critical care environment, aiming to use iNO in respiratory failure and pulmonary hypertension of adults or as a preventative measure of hemolysis-induced vasoconstriction, ischemia/reperfusion injury and as a potential treatment of renal failure associated with cardiopulmonary bypass. In this narrative review we aim to present a comprehensive summary of the potential use of iNO in several clinical conditions with its suggested benefits, including its recent application in the scenario of the COVID-19 pandemic. Randomized controlled trials, meta-analyses, guidelines, observational studies and case-series were reported and the main findings summarized. Furthermore, we will describe the toxicity profile of NO and discuss an innovative proposed strategy to produce iNO. Overall, iNO exhibits a wide range of potential clinical benefits, that certainly warrants further efforts with randomized clinical trials to determine specific therapeutic roles of iNO.

Indexed as

Critical IllnessAdultCOVID-19COVID-19 Drug TreatmentHumansHypertension, PulmonaryInfant, NewbornInfant, Newborn, DiseasesNitric OxideSARS-CoV-2Vasodilator AgentsNitric OxideVasodilator AgentsClinical applicationsCOVID-19Critically illIschemia/reperfusion injuryNitric oxidePulmonary hypertensionToxicology

Identifiers

PMID35123061
PMCPMC10189363
OpenAlexW4212833085

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.